Paper37056757
The transdermal cream of Formestane anti-breast cancer by controlling PI3K-Akt pathway and the tumor immune microenvironment.
Gao L and 9 others. Front Immunol, 2023. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. The transdermal cream of Formestane anti-breast cancer by controlling PI3K-Akt pathway and the tumor immune microenvironment. Papers, record 37056757. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37056757
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The transdermal cream of Formestane anti-breast cancer by controlling PI3K-Akt pathway and the tumor immune microenvironment.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Proto-Oncogene Proteins c-akt | Major topic |
| Mammary Neoplasms, Animal | Major topic |
| Rats | |
| Animals | |
| Phosphatidylinositol 3-Kinases | |
| CD8-Positive T-Lymphocytes | |
| Tumor Microenvironment | |
| Androstenedione |
Source PubMed
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23982470 | BTG1 inhibits breast cancer cell growth through induction of cell cycle arrest and apoptosis. | Oncol Rep | 2013 | https://conductscience.org/library/papers/23982470 | PubMed |
| 2 | 26206099 | Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. | Expert Opin Biol Ther | 2015 | https://conductscience.org/library/papers/26206099 | PubMed |
| 3 | 16723503 | LRRC4, a putative tumor suppressor gene, requires a functional leucine-rich repeat cassette domain to inhibit proliferation of glioma cells in vitro by modulating the extracellular signal-regulated kinase/protein kinase B/nuclear factor-kappaB pathway. | Mol Biol Cell | 2006 | https://conductscience.org/library/papers/16723503 | PubMed |
| 4 | 31942075 | B cells and tertiary lymphoid structures promote immunotherapy response. | Nature | 2020 | https://conductscience.org/library/papers/31942075 | PubMed |
| 5 | 20535542 | Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. | Breast Cancer Res Treat | 2010 | https://conductscience.org/library/papers/20535542 | PubMed |
| 6 | 9690562 | Antiproliferative gene BTG1 is highly expressed in apoptotic cells in macrophage-rich areas of advanced lesions in Watanabe heritable hyperlipidemic rabbit and human. | Lab Invest | 1998 | https://conductscience.org/library/papers/9690562 | PubMed |
| 7 | 6150277 | 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. | Lancet | 1984 | https://conductscience.org/library/papers/6150277 | PubMed |
| 8 | 31235695 | The beneficial androgenic action of steroidal aromatase inactivators in estrogen-dependent breast cancer after failure of nonsteroidal drugs. | Cell Death Dis | 2019 | https://conductscience.org/library/papers/31235695 | PubMed |
| 9 | 11822752 | Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? | Ann Oncol | 2001 | https://conductscience.org/library/papers/11822752 | PubMed |
| 10 | 28103936 | Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells. | Breast Cancer Res | 2017 | https://conductscience.org/library/papers/28103936 | PubMed |
| 11 | 12943750 | Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? | J Steroid Biochem Mol Biol | 2003 | https://conductscience.org/library/papers/12943750 | PubMed |
| 12 | 31406251 | Dynamic interactions between the extracellular matrix and estrogen activity in progression of ER+ breast cancer. | Oncogene | 2019 | https://conductscience.org/library/papers/31406251 | PubMed |
| 13 | 25526788 | Function and mechanism of tumor suppressor gene LRRC4/NGL-2. | Mol Cancer | 2014 | https://conductscience.org/library/papers/25526788 | PubMed |
| 14 | 23529824 | Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer. | Drugs | 2013 | https://conductscience.org/library/papers/23529824 | PubMed |
| 15 | 31942077 | B cells are associated with survival and immunotherapy response in sarcoma. | Nature | 2020 | https://conductscience.org/library/papers/31942077 | PubMed |
| 16 | 33846305 | Atlas of breast cancer infiltrated B-lymphocytes revealed by paired single-cell RNA-sequencing and antigen receptor profiling. | Nat Commun | 2021 | https://conductscience.org/library/papers/33846305 | PubMed |
| 17 | 109701 | Aromatase inhibitors--IV. Regression of hormone-dependent, mammary tumors in the rat with 4-acetoxy-4-androstene-3,17-dione. | J Steroid Biochem | 1979 | https://conductscience.org/library/papers/109701 | PubMed |
| 18 | 7850806 | Overexpression of DAN gene product in normal rat fibroblasts causes a retardation of the entry into the S phase. | Cancer Res | 1995 | https://conductscience.org/library/papers/7850806 | PubMed |
| 19 | 29968419 | Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy. | Angew Chem Int Ed Engl | 2018 | https://conductscience.org/library/papers/29968419 | PubMed |
| 20 | 28719035 | Melatonin inhibits nucleus pulposus (NP) cell proliferation and extracellular matrix (ECM) remodeling via the melatonin membrane receptors mediated PI3K-Akt pathway. | J Pineal Res | 2017 | https://conductscience.org/library/papers/28719035 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42219404 | Transdermal drug delivery systems in cancer therapy: advances, challenges, and future perspectives. | Eur J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/42219404 | PubMed |
| 39676967 | Novel Glycyrrhetin Ureas Possessing 2-Hydroxy-3-enone A Ring: Modification, Anti-inflammatory Activity, and Targeted STING for the Remedy of Acute Kidney Injury. | ACS Omega | 2024 | https://conductscience.org/library/papers/39676967 | PubMed |
| 39343994 | Nanoemulsion-based transdermal delivery of third-generation steroidal and non-steroidal aromatase inhibitors in preclinical models. | Cell Prolif | 2025 | https://conductscience.org/library/papers/39343994 | PubMed |
| 38765245 | Distinct mechanisms of iron and zinc metal ions on osteo-immunomodulation of silicocarnotite bioceramics. | Mater Today Bio | 2024 | https://conductscience.org/library/papers/38765245 | PubMed |
Genes27
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37056757
GET https://conductscience.org/api/papers/v1/37056757/references?page=2